Eyecelerator 2020 Presentation
November 10, 2020
Trefoil provided an update on the company and its clinical program for TTHX1114 at the inaugural Eyecelerator 2020 virtual conference on November 6. TTHX1114 is the company’s first-in-class, engineered fibroblast growth factor 1 (FGF-1), for the regenerative treatment of corneal diseases.
Cookie Consent
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Cookie Preferences
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Name
Description
Duration
Cookie Preferences
This cookie is used to store the user's cookie consent preferences.
30 days
